⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

Lonza Group and NeuroSense partner for ALS biomarker research

Published 09/04/2024, 14:14
LONN
-
NRSN
-

BASEL, Switzerland - Lonza Group Ltd (SIX: LONN), a key player in the pharmaceutical development and manufacturing sector, and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a biotech company specializing in neurodegenerative diseases, have announced a collaboration aimed at enhancing the understanding and treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS).

The partnership will focus on the development and optimization of methods to measure biomarkers from neuron-derived exosomes (NDEs), which will be incorporated into the clinical development of NeuroSense's lead product candidate, PrimeC.

NeuroSense, leveraging its expertise in biomarker utilization, will gain access to Lonza's advanced extracellular vesicles capabilities on an 'on-demand' basis. Lonza will contribute its extensive experience in the exosome field to the partnership, having invested in the area over the past decade, including the acquisition of Exosomics.

Davide Zocco, Head of Exosomes Development at Lonza, expressed the company's commitment to supporting innovators in advancing their therapies. Alon Ben-Noon, CEO of NeuroSense, highlighted the potential impact of the collaboration on early diagnosis and treatment of neurodegenerative diseases, as well as the regulatory pathway for new treatments.

NeuroSense recently reported positive results from the six-month double-blind phase of its Phase 2b PARADIGM trial of PrimeC in ALS patients. The trial demonstrated a statistically significant slowing of disease progression in the per protocol population when compared to a placebo. Further biomarker and efficacy endpoints from the trial are expected to be reported in the first half of 2024.

PrimeC, a novel oral formulation combining ciprofloxacin and celecoxib, aims to target several key mechanisms of ALS. It has been granted Orphan Drug Designation by the FDA and EMA. NeuroSense is committed to developing therapies for ALS, Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases, which remain areas of high unmet medical need.

This collaboration, based on a press release statement.

InvestingPro Insights

In light of NeuroSense Therapeutics Ltd.'s (NASDAQ: NRSN) recent collaboration with Lonza Group for advancing the treatment of neurodegenerative diseases, investors may find the following InvestingPro insights particularly relevant. NeuroSense has displayed a strong return over the last three months, with a 110.65% price total return, and an even more impressive six-month price total return of 230.17%. These metrics underscore the market's response to the company's progress, especially considering the positive results from their Phase 2b PARADIGM trial.

Despite these promising returns, InvestingPro Tips suggest that caution may be warranted. NeuroSense holds more cash than debt on its balance sheet, which is a positive indicator of financial stability. However, the company is quickly burning through cash and suffers from weak gross profit margins. Moreover, their short-term obligations exceed their liquid assets, and they have not been profitable over the last twelve months, as reflected by a negative P/E ratio of -2.11. These factors could signal financial challenges ahead, particularly as the company continues to invest in its clinical trials and research endeavors.

Investors considering NeuroSense as a potential addition to their portfolio should note that the company does not pay dividends, which may be a consideration for those seeking regular income. For those interested in a deeper dive into NeuroSense's financial health and future prospects, there are additional InvestingPro Tips available. By using the coupon code PRONEWS24, investors can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing access to comprehensive analysis and more exclusive insights.

As NeuroSense continues to navigate the complex landscape of neurodegenerative disease treatment, staying informed through resources like InvestingPro can help investors make more educated decisions. With the next earnings date set for May 29, 2024, stakeholders will be keenly awaiting further developments and the potential impact of the collaboration with Lonza on the company's financial performance and therapeutic advancements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.